Open dataset · verified Sep 22, 2026 (ET)
Peptide legal status, country by country
19 peptides, six regulators, one grid. Every cell is a dated status taken from the regulator's own publications - select any cell for the detail, or open a compound for its sources.
What the grid shows
1 of 19
can be lawfully compounded anywhere in this grid - Sermorelin, in the United States only.
14 of 19
are In limbo in the United States - and nowhere else. It is the one place where the headlines and the law disagree.
11 of 19
are restricted in every one of Australia, the United Kingdom, the European Union and Canada.
14 of 19
are prohibited in sport at all times under the WADA Prohibited List.
Under review The only live review in the grid: Cagrilintide in Canada.
Select any cell to read what that regulator's status means for that compound.
How to read each column
The five states are the same everywhere, but each regulator answers a slightly different legal question. Reading across a row compares answers, not identical tests.
- United States · FDA
- Whether a licensed pharmacy may compound it under Section 503A - the question most people are really asking. In limbo occurs only here, because only the FDA has held advisory votes it has not yet acted on.
- Australia · TGA
- Scheduling under the Poisons Standard. Unscheduled means the compound is not named in the Standard - not that it may be sold: supplying an unregistered medicine for human use still requires ARTG registration.
- United Kingdom · MHRA · European Union · EMA
- Whether a marketing authorisation exists. Without one, supplying it as a medicine is unlawful; in the EU, enforcement sits with each member state.
- Canada · Health Canada
- Authorization in the Drug Product Database and the Prescription Drug List. Under review means a drug submission has been accepted and no decision has been made.
- Sport · WADA
- The World Anti-Doping Code, which binds athletes, not the public. Restricted here means prohibited at all times, in and out of competition.
The five states
- Under review
- Actively before the FDA advisory committee; a decision is pending and the status can move.
- In limbo
- Moved on paper - nominated, removed from a restricted list, or recommended by an FDA committee - but not added to the 503A list. The headline implies a change; the legal status has not moved.
- Restricted
- Prescription-only, banned, controlled, or under active FDA enforcement.
- Compounding-legal
- On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.
- Unscheduled
- No specific federal action; unaddressed at this time.
Use this data
Journalists, researchers, clinicians and app builders are welcome to it. It is free under CC BY 4.0: credit Peptlas and link back to this page, and the numbers stay traceable to their sources.
Download
One row per compound and jurisdiction: status, plain-language note, entry link and the verified date. The files rebuild whenever a status changes.
Cite
Peptlas Research Team (2026). Peptide legal status by country [Data set]. Peptlas. https://peptlas.com/peptide-status-by-country/ (verified Sep 22, 2026 (ET)).
Embed the live grid
<iframe src="https://peptlas.com/embed/peptide-status-matrix/" title="Peptide legal status by country - Peptlas" width="100%" height="760" style="border:0" loading="lazy"></iframe> <p style="font:13px/1.4 system-ui,sans-serif">Data: <a href="https://peptlas.com/peptide-status-by-country/">Peptlas - peptide legal status by country</a> (CC BY 4.0)</p>
The embed updates itself when a status changes, so an article never goes stale. For a single compound, each entry page offers a status badge.
Questions this grid answers
- Which peptides are legal to compound in the United States?
- Of the 19 compounds Peptlas tracks, only Sermorelin can currently be compounded by a licensed pharmacy under Section 503A. 14 are In limbo - nominated, removed from a restricted list, or recommended by an FDA advisory committee, but not added to the 503A list - and the rest are restricted.
- Why does the U.S. column say "In limbo" when other countries say "Restricted"?
- In limbo is the gap between a headline and the law. In July 2026 an FDA advisory committee recommended six peptides for the 503A list, and much of the internet read that as legalization. The vote is advisory: until the FDA completes rulemaking, none of them can lawfully be compounded. Other regulators have no equivalent half-step, so their answer is simply restricted.
- Is BPC-157 legal in Australia, the UK, the EU or Canada?
- No. BPC-157 is restricted in Australia, the United Kingdom, the European Union and Canada, and WADA prohibits it in sport at all times. In the United States it is In limbo: recommended by an FDA advisory committee in July 2026, but still not on the 503A list.
- Are these peptides banned in sport?
- WADA prohibits 14 of the 19 at all times. The exceptions are GHK-Cu, NAD+, Semaglutide, Thymosin Alpha-1 and Tirzepatide, which are not on the Prohibited List by name. Sport rules apply to athletes under the World Anti-Doping Code, not to the general public.
- Can I reuse this data?
- Yes. The dataset is published under CC BY 4.0: you may copy, chart and republish it, including commercially, as long as you credit Peptlas and link to this page. CSV and JSON downloads are on this page.
- How current is it?
- Every row was last verified by hand on Sep 22, 2026 (ET). The U.S. column is re-checked against FDA sources every six hours; the other jurisdictions change far less often and are re-verified in a monthly sweep. When a status changes, the entry page, this grid and the downloads update together.